Improvement of Early ¹⁸F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background

Abstract

When assessing early response, particularly in risk-adapted therapeutic trials, it seems preferable to refer to a background tissue (liver) with a higher level of uptake than that of current international criteria (MBP) which were designed for end-of-treatment evaluation.